← UroGen Pharma Ltd. (URGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
UroGen Pharma Ltd. (URGN)
Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
UroGen Pharma (URGN) is a specialty pharmaceutical company focused on uro-oncology, with a market cap of ~$1.94B and 287 employees. The company has multiple Phase 3 assets targeting bladder cancer and upper urinary tract urothelial carcinoma (UTUC), with UGN-101 as the lead. Revenue is growing but the company burns cash heavily, carrying net debt of $90M and only ~7.3 months of runway.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-03-15 (est.)Phase 3 · UGN-104imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 120 mg MMC in 90ml gel | Phase 2 | Bladder Cancer |
| UGN-101 instillations | Phase 3 | Carcinoma, Transitional Cell |
| UGN-102 | Phase 3 | Bladder Cancer |
| UGN-104 | Phase 3 | Upper Urinary Tract Urothelial Carcinoma |
| UGN-103 | Phase 3 | Bladder Cancer |
Price & technical context
3-month
+6.7%
6-month
+114.1%
12-month
+103.3%
52-wk range
$16.42–$50.29
vs 50-day MA
-7.5%
vs 200-day MA
+35.9%
Realized vol
62.5%
Max drawdown
-71.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for URGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.